C12N 2770/36211
Rubivirus
Official title: Rubivirus, e.g. rubella virus
C12N2770/36211 (Rubivirus) appears on 66 US grants and 70 published applications in this corpus.
Search patents in C12N- Granted patents
- 66
- Published applications
- 70
- Assignees
- 62
- Inventors
- 177
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 0 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 8 |
| 2004 | 2 | 3 |
| 2005 | 2 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 1 | 3 |
| 2009 | 3 | 3 |
| 2010 | 0 | 5 |
| 2011 | 2 | 2 |
| 2012 | 1 | 1 |
| 2013 | 2 | 1 |
| 2014 | 2 | 4 |
| 2015 | 2 | 3 |
| 2016 | 0 | 4 |
| 2017 | 1 | 4 |
| 2018 | 3 | 3 |
| 2019 | 4 | 3 |
| 2020 | 2 | 3 |
| 2021 | 2 | 3 |
| 2022 | 2 | 3 |
| 2023 | 3 | 2 |
| 2024 | 3 | 3 |
| 2025 | 1 | 5 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/36234Use of virus or viral component as vaccineIndexing code31
- C12N 2770/36222New viral proteins or individual genes, new structural or functional aspects ofIndexing code27
- C12N 2770/36251Methods of production or purification of viral materialIndexing code8
- C12N 2770/36221Viruses as suchIndexing code4
- C12N 2770/36241Use of virus, viral particle or viral elements as a vectorIndexing code4
- C12N 2770/36261Methods of inactivation or attenuationIndexing code4
- C12N 2770/36223Virus like particles [vlp]Indexing code1
- C12N 2770/36232Use of virus as therapeutic agent, other than vaccineIndexing code1
Recent patents
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- Compositions and methods for stabilization of active agents22 Apr 2025US 12,280,101 B2Trustees of Tufts College
- Modulation of replicative fitness by deoptimization of synonymous codons17 Sep 2024US 12,090,197 B2The Government of the USA, as represented by the Secretary, Department of Health and Human Services
- Method of detecting antibodies against JEV or ZIKV using recombinant baculoviruses expressing prM/e30 Jul 2024US 12,050,216 B2Chung Yuan Christian University
- Identifying patient populations vulnerable to viral infection and methods of inducing heterologous immunity in same26 Mar 2024US 11,938,181 B2nference, Inc.
- Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen30 Oct 2025US 2025/0332250 A1SK Bioscience Co., Ltd.
- Composition for reducing size or volume of target tissue or kit including same4 Sep 2025US 2025/0276028 A1SK Bioscience Co., Ltd.
- Melting Microneedle Patches and Methods of Manufacturing Thereof29 May 2025US 2025/0170379 A1Georgia Tech Research Corporation
- Signal sequences for nucleic acid vaccines22 May 2025US 2025/0161425 A1Sanofi
- Freeze-dried viral combination vaccine compositions and process for preparation thereof20 Feb 2025US 2025/0057939 A1Codagenix Inc.
Most cited
By later US patents
- Materials and methods for treatment of plaquing diseases96US 5,851,996 AMilkhaus Laboratory, Inc. · 1998
- Materials and methods for treatment of plaquing disease92US 5,753,624 AMilkhaus Laboratory, Inc. · 1998
- Baculovirus dual promoter expression vector44US 5,169,784 AThe Texas A&M University System · 1992
- Peptides representing epitopic sites for bacterial and viral meningitis causing agents and their CNS carrier and uses thereof40US 5,556,757 AInsight Biotek, Inc. · 1996
- Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell40US 6,825,036 B2Juridical Foundation The Chemo-Sero-Therapeutic Research Institute · 2004